Brain dam­age cas­es force an FDA hold on Bel­licum's lead cell ther­a­py -- shares tank

Bel­licum Phar­ma­ceu­ti­cals $BLCM just fell even fur­ther be­hind the pack lead­ers in the cell ther­a­py crowd.

The Hous­ton-based biotech re­port­ed af­ter the mar­kets closed Tues­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER